Cancer Epidemiology Biomarkers & Prevention, Vol 7, Issue 4 329-333, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Hormone replacement therapy and risk of colon and rectal cancer

E Fernandez, C La Vecchia, C Braga, R Talamini, E Negri, F Parazzini and S Franceschi
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. efernandez@bell.ub.es

The hypothesis that sex hormones may influence colorectal cancer risk was formulated in the early 1980s, but epidemiological studies on a relationship between colorectal cancer risk and hormone replacement therapy (HRT) have only accumulated over the last few years. To investigate the relationship between HRT and colon and rectal cancer and the role of other covariates that might modify it, we analyzed combined data from two case-control studies conducted in Italy between 1985 and 1996, including 994 women with incident colon cancer, 542 with rectal cancer, and 3110 controls with acute, non-neoplastic, nondigestive, non-hormone-related disorders. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from unconditional multiple logistic regression equations including terms for age, center/study period, education, family history of colorectal cancer, status and age at menopause, parity, use of oral contraceptives, total energy intake, and body mass index. Ever use of HRT was inversely associated with cancer of the colon (OR = 0.64, 95% CI = 0.46-0.88) and of the rectum (OR = 0.46, 95% CI = 0.29-0.72). Increasing duration of use of HRT was related to decreasing risk for colon and rectal cancers (P for trend < 0.01). No interaction emerged, and the inverse association persisted across separate strata of other risk factors. This study, one of the largest case-control investigations on exogenous female hormones and colorectal cancer thus far, provides further evidence that women who have ever used HRT are at lower risk of colon and rectal cancer. Because colorectal cancer is the second most common neoplasm and cause of death among nonsmoking women in developed countries, these results may have a major public health impact.

This article has been cited by other articles:

				J. Hippisley-Cox, Y. Vinogradova, C. Coupland, and C. Parker Risk of Malignancy in Patients With Schizophrenia or Bipolar Disorder: Nested Case-Control Study Arch Gen Psychiatry, December 1, 2007; 64(12): 1368 - 1376. [Abstract] [Full Text] [PDF]

				L. A. Wolf, P. D. Terry, J. D. Potter, and R. M. Bostick Do Factors Related to Endogenous and Exogenous Estrogens Modify the Relationship between Obesity and Risk of Colorectal Adenomas in Women? Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 676 - 683. [Abstract] [Full Text] [PDF]

				J. A. Chan, J. A. Meyerhardt, A. T. Chan, E. L. Giovannucci, G. A. Colditz, and C. S. Fuchs Hormone Replacement Therapy and Survival After Colorectal Cancer Diagnosis J. Clin. Oncol., December 20, 2006; 24(36): 5680 - 5686. [Abstract] [Full Text] [PDF]

				M. Cotterchio, B. A. Boucher, M. Manno, S. Gallinger, A. Okey, and P. Harper Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk J. Nutr., December 1, 2006; 136(12): 3046 - 3053. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F. A. Hubbell, J. Ascensao, R. J. Rodabough, C. A. Rosenberg, V. M. Taylor, R. Harris, C. Chen, et al. Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women N. Engl. J. Med., March 4, 2004; 350(10): 991 - 1004. [Abstract] [Full Text] [PDF]

				B. T. Levy, J. M. Ritchie, E. Smith, T. Gray, and W. Zhang Physician Specialty Is Significantly Associated With Hormone Replacement Therapy Use Obstet. Gynecol., January 1, 2003; 101(1): 114 - 122. [Abstract] [Full Text] [PDF]

				E. Kallay, H. Adlercreutz, H. Farhan, D. Lechner, E. Bajna, W. Gerdenitsch, M. Campbell, and H. S. Cross Phytoestrogens Regulate Vitamin D Metabolism in the Mouse Colon: Relevance for Colon Tumor Prevention and Therapy J. Nutr., November 1, 2002; 132(11): 3490S - 3493. [Abstract] [Full Text] [PDF]

				K. Woodson, E. Lanza, J. A. Tangrea, P. S. Albert, M. Slattery, J. Pinsky, B. Caan, E. Paskett, F. Iber, J. W. Kikendall, et al. Hormone Replacement Therapy and Colorectal Adenoma Recurrence Among Women in the Polyp Prevention Trial J Natl Cancer Inst, December 5, 2001; 93(23): 1799 - 1805. [Abstract] [Full Text] [PDF]

				D. Brighouse Hormone replacement therapy (HRT) and anaesthesia Br. J. Anaesth., May 1, 2001; 86(5): 709 - 716. [Abstract] [Full Text] [PDF]

				D. F. ARCHER and J. H. PICKAR Hormone Replacement Therapy: Effect of Progestin Dose and Time Since Menopause on Endometrial Bleeding Obstet. Gynecol., December 1, 2000; 96(6): 899 - 905. [Abstract] [Full Text] [PDF]

				L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]

				P. A. Janne and R. J. Mayer Chemoprevention of Colorectal Cancer N. Engl. J. Med., June 29, 2000; 342(26): 1960 - 1968. [Full Text] [PDF]

				N. Prihartono, J. R. Palmer, C. Louik, S. Shapiro, and L. Rosenberg A Case-Control Study of Use of Postmenopausal Female Hormone Supplements in Relation to the Risk of Large Bowel Cancer Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 443 - 447. [Abstract] [Full Text]

				S. Gingras and J. Simard Induction of 3{beta}-Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines Endocrinology, October 1, 1999; 140(10): 4573 - 4584. [Abstract] [Full Text]

				J. D. Potter Colorectal Cancer: Molecules and Populations J Natl Cancer Inst, June 2, 1999; 91(11): 916 - 932. [Abstract] [Full Text] [PDF]